Lupus

Ten common mistakes in the management of lupus nephritis

Bose B, Silverman ED, Bargman JM
Am J Kidney Dis. 2014 Apr;63(4):667-76. doi: 10.1053/j.ajkd.2013.10.056. Epub 2013 Dec 12
Google Plus
LinkedIn

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study (LUNAR)

Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group
Arthritis Rheum. 2012 Apr;64(4):1215-26
Google Plus
LinkedIn

Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial

Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH; Dutch Working Party on Systemic Lupus Erythematosus
Kidney Int. 2006 Aug;70(4):732-42. Epub 2006 Jul 5
Google Plus
LinkedIn

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB
N Engl J Med. 2005 Nov 24;353(21):2219-28
Google Plus
LinkedIn

Sequential therapies for proliferative lupus nephritis

Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D
N Engl J Med. 2004 Mar 4;350(10):971-80
Google Plus
LinkedIn

The classification of glomerulonephritis in systemic lupus erythematosus revisited

Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M
J Am Soc Nephrol. 2004 Feb;15(2):241-50
Google Plus
LinkedIn

ukidneyisup